Rachel Gilmour

The Government has made no such specific assessment, as tariffs and energy contracts are a commercial matter for suppliers. However, the Government does want consumers to have access to a range of tariffs, so they can choose the contract that best suits their needs and can help to reduce energy bills. In circumstances where a supplier may not currently be able to offer a smart meter, Ofgem has been clear that suppliers are obligated under their licence conditions to ensure that a suitable metering system is installed.

The industry-led migration from analogue to digital landlines (“the PSTN migration”) poses some specific risks for rural constituencies, for instance where areas may be more prone to power outages or lack mobile coverage. The Department is working with communications providers to ensure that they are mitigating these risks wherever possible, for example by encouraging the industry to provide improved power resilience to vulnerable customers.

Since the general election, the government has brought together communications providers, government departments, local government, telecare providers and water companies to ensure that the transition proceeds smoothly and stably. This has led to a new Charters of Commitments signed by industry to ensure additional protections for vulnerable customers and for Critical National Infrastructure.

This government recognises the vital role that youth services and activities play in improving young people’s life chances and wellbeing. As set out in section 507B of the Education Act 1996, local authorities have a statutory duty to secure, so far as is reasonably practicable, sufficient provision of educational and recreational leisure-time activities for young people in their area. This is funded through the Local Government Settlement which amounts to over £60 billion this year.

This is in addition to the DCMS investment of over £500 million in youth services to ensure every young person has access to regular clubs and activities, adventures away from home and opportunities to volunteer. Within the Tiverton and Minehead constituency, DCMS has directly provided funding for Duke of Edinburgh to be run within schools, encouraging young people to develop skills, build confidence, and make a difference in their communities through volunteering, access to the outdoors, and skills development.

The department has no plans to undertake this specific assessment, but we have evaluated the impact of poverty on educational outcomes. Evidence shows that disadvantaged pupils and those with additional needs are more likely to fall behind and need extra support to achieve and thrive.

That is why the department is working to make sure that all children and young people have access to a variety of enrichment opportunities at school as an important part of our mission to break down barriers to opportunity. We recognise that these activities are a vital way for children and young people to gain skills and strengthen their sense of school belonging, supporting them to thrive.

The Department for Work and Pensions strives to set affordable and sustainable repayment plans and encourages customers to make contact if they are unable to afford the proposed repayment rate.

When a customer makes contact because they are experiencing financial hardship, the rate of repayment can be reduced or, depending on the customer’s financial circumstances, a temporary suspension of repayment can be agreed. There is no minimum amount a customer has to repay.

As seen in the measures announced by my right hon. Friend, the Chancellor of the Exchequer, in the Autumn Budget 2024 to drive up opportunity and drive down poverty, a new Fair Repayment Rate will be introduced from April 2025, reducing Universal Credit deductions overall cap from 25% to 15%. This measure will help approximately 1.2 million of the poorest households benefit by an average of £420 a year.

Ensuring schools have the resources and buildings they need is a key part of our mission to break down barriers to opportunity and give every child the best start in life.

My right hon. Friend, the Secretary of State for Education is unable to meet at present due to constraints on her diary. However, departmental officials will be in touch with you shortly to arrange a meeting with the honourable member who are best placed to provide detail on the condition of the school.

Defra welcomes the publication of the report, which is an output of work funded by UK Research and Innovation. We consider a number of policy initiatives already align with many of the work’s findings, and will continue to consider their implications in the further development of policy related to the management of fisheries and the marine environment.

My Defra private office handles all meeting requests. Please contact them directly to request a meeting.

Asulox is a herbicide containing the active substance asulam, which is not approved for use in the UK. For some years, use of Asulox to control bracken has been allowed under strictly controlled conditions under emergency authorisation arrangements. In 2023 the company behind asulam decided to cease supporting further applications for emergency authorisation and has not applied for UK approval of asulam. There are therefore no plans to restore the licence for Asulox or assess the potential impact of its restoration.

The Canal and River Trust is the largest inland waterway navigation authority in England and Wales, responsible for the 2,000 miles of canals and rivers it owns. The Government is currently providing the Trust with a 15-year grant (2012-2027) totalling about £740 million to support maintenance of the canal network infrastructure. A review of the grant funding concluded that the Trust is providing value for money and there was a good case for continued grant funding. A further substantial 10-year grant from 2027 of £401 million was announced in July 2023, reconfirmed by the Government in August 2024, reflecting the importance of the country’s inland waterways and supporting the Trust in the long-standing objective of reducing reliance on public funding while developing alternative funding sources.

The Government also provides grant-in-aid funding to the Environment Agency to support its 630 miles of navigations. This totalled around £70 million over the last three years. Future funding will be determined as part of the current spending review.

There is no other general Government funding available for inland waterways, and the other navigation authorities responsible for smaller waterway networks raise funds through their boat licensing regimes and other activities working with local communities.

Planning permission is always required to change use of a pub, ensuring that local consideration can be given to any such proposals through the planning application process, in consultation with the local community. Defra cannot comment on individual planning cases.

Officials continually monitor the performance of Great Western Railway services, including instances of overcrowding, and actively hold operators to account through their contracts when they run less capacity than agreed. The Rail Minister additionally meets with Train Operating Companies to review their performance. We work closely with Great Western Railway to match supply to demand within operational and financial constraints including the provision of additional summer services. Great Western Railway is also exploring opportunities to increase the capacity of its rolling stock fleet.

Good local bus services are an essential part of prosperous and sustainable communities. As announced in the King’s Speech, the government will pass the Better Buses Bill to put the power over local bus services back in the hands of local leaders right across England. The government knows that every community will have its own unique needs from its public transport network and wants to empower local leaders to work with operators to design networks that meet these needs, including considering the use of different types of services, such as community transport and demand responsive transport services, alongside regular stopping services to deliver comprehensive coverage.

DWP are committed to providing the best possible support for all our customers, including the most vulnerable in society. Within Universal Credit, we recognise that customers have individual needs and different barriers, so we train and support all our work coaches to be able to respond appropriately to a customer’s situation.

We have no plans to assess the impact of the journal system on the mental health of applicants and users., Independent research published in 2018 showed that the majority of customers found the journal easy to use. The DWP Customer Experience Survey for 2023-2024 showed that 88% of people found it easy to use their UC online account.

We have committed to develop a 10-Year Health Plan to deliver an National Health Service fit for the future, by driving three shifts in the way health care is delivered. We will carefully be considering policies, including those that impact people with palliative and end of life care needs, with input from the public, patients, health staff, and our stakeholders as we develop the plan.

One of the three shifts that the plan will deliver is around the Government’s determination to shift more healthcare out of hospitals and into the community. This includes our commitment to trial neighbourhood health centres, to ensure that patients receive personalised care in the most appropriate setting. Palliative and end of life care services, including hospices, will play an important role in our considerations of the services those centres should host. More information about how they can input into the 10-Year Health Plan is available at the following link:

https://change.nhs.uk/en-GB/

The Department funds research into epilepsy via the National Institute for Health and Care Research (NIHR). The NIHR spent almost £19 million on 46 epilepsy research projects in the five years from April 2019 to March 2024. Additionally, over this period, more than 9,500 people were enabled to participate in epilepsy research by the NIHR Clinical Research Network, now the NIHR Research Delivery Network.

The NIHR welcomes funding applications for research into any aspect of human health, including epilepsy. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.

The NIHR also works closely with other Government funders, including UK Research and Innovation, which is funded by the Department for Science, Innovation and Technology and includes the Medical Research Council, to fund research into epilepsy to improve treatments and prevent poor health outcomes for patients.

We want a society where every person, including those with long-term conditions such as epilepsy, receives high-quality, compassionate continuity of care, with their families and carers supported. We will change the National Health Service so that it becomes not just a sickness service, but one that is able to prevent ill health in the first place. This will help us be better prepared for the change in the nature of disease, and allow our services to focus more on the management of chronic, long-term conditions, including epilepsy.

At the national level, there are a number of initiatives supporting service improvement and better care for patients with epilepsy, including the RightCare Epilepsy Toolkit and the Getting It Right First Time Programme for Neurology, with further information on both available, respectively, at the following two links:

https://gettingitrightfirsttime.co.uk/academy-resources/population-health/

https://gettingitrightfirsttime.co.uk/medical_specialties/neurology/

NHS England has also established a Neurology Service Transformation Programme, a multi-year, clinically led programme to develop a new model of integrated care for neurology services, including for epilepsy.

In December 2023, the National Institute for Health and Care Excellence published the Technology Appraisal guidance, and recommended that the National Health Service in England makes Hybrid Closed Loop (HCL) systems available to eligible adults, and all children and young people, those under 19 years old, with type 1 diabetes. The NICE and NHS England agreed on a phased implementation period for HCL over five-years, and without the usual 90-day funding mandate. This is because of a need to build essential workforce competencies within specialist adult services. The NHS England HCL Implementation Strategy, published in January 2024, set out how local systems can meet the needs of the eligible population living with type 1 diabetes. The initial phase of the roll out of HCL systems started earlier this year, in April 2024. Further information on the HCL Implementation Strategy is available at the following link:

https://www.england.nhs.uk/long-read/hybrid-closed-loop-technologies-5-year-implementation-strategy/

The National Institute for Health and Care Excellence (NICE) is responsible for developing the methods and processes it uses in its evaluations independently, and in consultation with stakeholders. The severity modifier that the NICE introduced in 2022 is based on evidence of societal preferences, and was introduced as part of a comprehensive review of the NICE’s methods and processes, following extensive public and stakeholder engagement. The severity modifier was designed to be opportunity cost neutral in relation to the end of life modifier that it replaced, and to apply to a broader range of conditions than had benefited from the end of life modifier.

The NICE was unfortunately unable to recommend Enhertu (trastuzumab deruxtecan) for the treatment of HER2-low secondary breast cancer in its final guidance published in July 2024, despite the topic being awarded a severity weighting. Other drugs for advanced cancer, including breast cancer, have been approved using these methods.

No assessment has been made on the likely impact on appraisals of future breast cancer medicines. However, since its introduction, the severity modifier has resulted in a higher approval rate for cancer medicines than under the NICE’s previous methods, and has also allowed greater weight to be applied to non-cancer medicines that address a broader range of severe diseases, enabling the NICE to recommend medicines for conditions such as cystic fibrosis and hepatitis D. The NICE is keeping the impact of the severity modifier under review and is scoping further research into society’s preferences on how much additional weighting to give to health benefits for people with severe diseases.

Decisions on whether new medicines should be routinely funded by the National Health Service in England are taken by the National Institute for Health and Care Excellence (NICE) on the basis of an evaluation of a treatment’s costs and benefits. NICE’s methods are internationally respected, and have been developed through extensive work with industry, academics and the public to ensure they appropriately capture the costs and benefits, and best reflect social values. These are very difficult decisions to make, and it is important that they are made independently and based on the available evidence.

We understand that despite NICE instigating an exceptional pause in the process to allow for commercial negotiations to take place with the companies, Daiichi Sankyo and AstraZeneca, a deal to enable patient access to this treatment on the NHS in England has not been reached.

We know NICE’s announcement has come as a blow to many women and their families. We understand that NICE and NHS England have already sought to apply as much flexibility as they can in their considerations of Enhertu and have made it clear to the companies that their pricing of the drug remains the main obstacle to access.

Within 16 weeks of the publication of final guidance, companies can also request a rapid review to consider new patient access scheme proposals, with the aim of establishing a pricing agreement that would improve cost-effectiveness and enable patient access to high-cost medicines. The Government wants to see a deal reached to make Enhertu available. NICE and NHS England remain open to considering an improved offer from the companies through the rapid review process, and we strongly encourage the companies to come back to the table.